Athersys Inc. (ATHX)’s Financial Results Comparing With Xencor Inc. (NASDAQ:XNCR)

We will be contrasting the differences between Athersys Inc. (NASDAQ:ATHX) and Xencor Inc. (NASDAQ:XNCR) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athersys Inc. 23.95M 9.17 26.06M -0.21 0.00
Xencor Inc. 48.75M 41.30 55.28M -0.77 0.00

Table 1 showcases the gross revenue, earnings per share (EPS) and valuation of Athersys Inc. and Xencor Inc.

Profitability

Table 2 shows us Athersys Inc. and Xencor Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Athersys Inc. -108.81% -58.7% -44.6%
Xencor Inc. -113.39% -13.4% -11.8%

Volatility & Risk

A beta of -0.5 shows that Athersys Inc. is 150.00% less volatile than Standard and Poor’s 500. Competitively, Xencor Inc.’s 80.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 1.8 beta.

Liquidity

The Current Ratio and Quick Ratio of Athersys Inc. are 4.6 and 4.6 respectively. Its competitor Xencor Inc.’s Current Ratio is 5.5 and its Quick Ratio is 5.5. Xencor Inc. can pay off short and long-term obligations better than Athersys Inc.

Analyst Ratings

In next table is given Athersys Inc. and Xencor Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Athersys Inc. 0 0 0 0.00
Xencor Inc. 0 0 2 3.00

On the other hand, Xencor Inc.’s potential upside is 39.66% and its consensus target price is $50.

Insider and Institutional Ownership

Roughly 22.7% of Athersys Inc. shares are owned by institutional investors while 84.1% of Xencor Inc. are owned by institutional investors. Insiders owned roughly 2.2% of Athersys Inc.’s shares. Competitively, 0.9% are Xencor Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Athersys Inc. 2.6% 0.51% 2.6% -19.26% 5.91% 8.84%
Xencor Inc. -10.69% -10% -6.5% -10.13% 68.55% 71.17%

For the past year Athersys Inc. has weaker performance than Xencor Inc.

Summary

On 7 of the 11 factors Xencor Inc. beats Athersys Inc.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies. Its product candidates also comprise XmAb5574/MOR208, which is in Phase II clinical trials for the treatment of non-Hodgkin lymphomas and chronic lymphocytic leukemia; and XmAb13551 that is in preclinical trials used for the treatment of multiple myeloma. The company has license agreement with Amgen Inc. and MorphoSys Ag to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.